Cyclerion reports Q3 net loss $11.3M, cash $63M; pipeline advances in CIAS, ADv, MELAS

Cyclerion Therapeutics, Inc.

2022-Q3 EPS reported -$1.08 revenue$3,409,000

Net loss of $11.3M improved from $18.8M in Q3 2020; R&D expenses down to $7.0M.
Cash, cash equivalents, and restricted cash $63M, down from $70M at June 30, 2021.
First patients enrolled in CIAS study (CY6463); patient screening underway in ADv study.
MELAS study enrollment slowed by COVID-19; topline clinical results expected H1 2022.
G&A expenses decreased to $4.6M from $8.0M, driven by lower salaries and financing fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.